MEGAN BELL: Open Payments
NPI 1912509399 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$786 in 39 payments from 18 companies in 2025. Trend: 2023 $521 · 2024 $404 · 2025 $786
Food & beverage: $786
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| Hologic Sales and Service, LLC | 3 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Exeltis, USA Inc. | 2 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| Exact Sciences Corporation | 2 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
Products named: VRAYLAR, CAPLYTA, GEMTESA, JARDIANCE, THIRD WAVE, FANAPT, SLYND, REXULTI.
Industry payments across MO — which companies pay providers there.
